search
Back to results

Olive Polyphenols in Cardiovascular Prevention.

Primary Purpose

Metabolic Syndrome, High Blood Pressure, High Cholesterol

Status
Recruiting
Phase
Phase 4
Locations
Belgium
Study Type
Interventional
Intervention
Tensiofytol
Cholesfytol NG
Placebo
Sponsored by
Nina Hermans
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Metabolic Syndrome

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • LDL cholesterol level ≥ 160 mg/dL (corrected for LP(a))
  • Metabolic syndrome as defined by ATPIII-criteria: at least 3 of the following 5 criteria, but certainly high blood pressure:

    1. Blood pressure ≥ 130/85 mg Hg or blood pressure medication (arterial hypertension)
    2. Waist circumference > 102 cm for men or > 88 cm for women
    3. Triglycerides ≥ 150mg/dL
    4. HDL cholesterol < 40mg/dL for men or < 50mg/dL for women
    5. Fasting glucose ≥ 110 mg/dL

Exclusion Criteria:

  • <18 jaar
  • >70 jaar
  • Smoking
  • Use of nutritional supplemenrs
  • Use of cholesterol lowering medication or other medication except for blood pressure medication
  • Triglycerides > 400 mg/dL
  • > 2 alcoholic consumptions/day
  • Chronic illness (e.g. diabetes, atherosclerosis, reumatoid arthritis)
  • Acute infection
  • Current pregnancy or pregnancy wish during the study period
  • Breast feeding

When nutritional supplements were used regularly, participation is allowed after a 10-day wash out period. Subjects who used cholesterol lowering medication or nutritional supplements with red yeast rice, can participate after a 6-week wash out.

Sites / Locations

  • UAntwerp, NatuRARecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

Standardized olive extract (Tensiofytol)

Combination preparation (Cholesfytol NG)

Placebo

Arm Description

3 capsules/day during dinner Per day: 334 mg olive leave dry extract and 106 mg olive fruit dry extract (Olea europaea), equivalent to 100 mg oleuropein and 20 mg hydroxytyrosol

3 capsules/day during dinner Per day: 67.2 mg red yeast rice powder (Monascus purpureus; equivalent to 2.9 mg monacoline K) 1000 mg amla dry extract (Phyllanthus emblica) 100 mg walnut leave dry extract (Juglans regia) 50 mg olive dry extract (Olea europaea; equivalent to 10 mg hydroxytyrosol)

3 capsules/day during dinner

Outcomes

Primary Outcome Measures

Change from baseline Blood Pressure at 8 weeks
average of 3 measurements during 15 minutes
Change from baseline Blood Pressure at 4 weeks
average of 3 measurements during 15 minutes
Change from baseline LDL cholesterol level at 8 weeks
Calculated from Total Cholesterol, HDL Cholesterol and Triglycerides
Change from baseline HDL cholesterol level at 8 weeks
Measurement in Serum
Change from baseline total cholesterol level at 8 weeks
Measurement in Serum
Change from baseline triglycerides level at 8 weeks
Measurement in Serum
Change from baseline glucose level at 8 weeks
Measurement in Fluoride Plasma
Change from baseline insuline level at 8 weeks
Required to correctly interpret glucose levels, Measurement in Serum
Change from baseline Apo A1 level at 8 weeks
Measurement in Serum
Change from baseline Apo B level at 8 weeks
Measurement in Serum
Change from baseline homocysteine level at 8 weeks
Measurement in Homocysteine Serum
Change from baseline lipoprotein A (LP(a)) level at 8 weeks
Measurement in Serum
Change from baseline hs-CRP level at 8 weeks
Measurement in Serum
Change from baseline creatinine level at 8 weeks
Required to correctly interpret HbAc1 levels, Measurement in Serum
Change from baseline HbA1c level at 8 weeks
Measurement in EDTA Whole Blood
Change from baseline hemoglobine level at 8 weeks
Required to correctly interpret HbAc1 levels, Measurement in EDTA Whole Blood
Change from baseline OxLDL level at 8 weeks
Measurement with ELISA
Change from baseline gluathion (GSH) level at 8 weeks
Measurement with in house HPLC method
Change from baseline malondialdehyde (MDA) level at 8 weeks
Measurement with ELISA

Secondary Outcome Measures

Change from baseline creatine kinase (CK) level at 8 weeks
Measurement with ELISA
Change from baseline Body Mass Index (BMI) at 8 weeks
weight and height will be combined to report BMI in kg/m^2
Change from baseline waist circumference at 8 weeks
Measurement with measuring tape
Frequency of side effects (+ their burden) as reported in the final questionnaire
Unvalidated but standardized questionnaire on typical statin-related side effects

Full Information

First Posted
April 27, 2021
Last Updated
November 22, 2022
Sponsor
Nina Hermans
Collaborators
University Hospital, Antwerp
search

1. Study Identification

Unique Protocol Identification Number
NCT04874961
Brief Title
Olive Polyphenols in Cardiovascular Prevention.
Official Title
Olive Polyphenols in Cardiovascular Prevention: Efficacy and Tolerability of a Commercially Available Standardized Olive Extract (Tensiofytol) as Compared to a Combination Preparation (Cholesfytol NG) and Placebo in Metabolic Syndrome: a RDBPC Trial.
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
May 20, 2021 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Nina Hermans
Collaborators
University Hospital, Antwerp

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of this study is to evaluate whether the use of a commercially available standardized olive extract (Tensiofytol) and a commercially available combination preparation (Cholesfytol NG) by individuals with metabolic syndrome Leads to a clinically relevant reduction of blood pressure on the short term, Leads to a clinically relevant reduction of cholesterol levels, especially LDL, Leads to a change in oxidative stress biomarkers. Participants will be stratified by sex and menopausal status before randomization to one of the three treatments for 8 weeks: Tensiofytol: 100 mg oleuropein and 20 mg hydroxytyrosol per day Cholesfytol NG: 2.9 mg monacoline K and 10 mg hydroxytyrosol per day Placebo All treatments have an identical shape and color and should be used in the same way (oral intake; 3 capsules/day during dinner). No dietary instructions are given and participants are asked not to change their dietary habits, nor to start other therapies (medication, supplements, slimming diets, extra physical activity, etc.) during their study period. Standardized questionnaires are used to obtain information on demographics, dietary habits and side effects. At baseline and after 8 weeks, 27 ml blood is drawn for various biological analyses, and blood pressure, BMI and waist circumference are measured.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metabolic Syndrome, High Blood Pressure, High Cholesterol, Dyslipidemias, High Blood Sugar

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
75 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Standardized olive extract (Tensiofytol)
Arm Type
Experimental
Arm Description
3 capsules/day during dinner Per day: 334 mg olive leave dry extract and 106 mg olive fruit dry extract (Olea europaea), equivalent to 100 mg oleuropein and 20 mg hydroxytyrosol
Arm Title
Combination preparation (Cholesfytol NG)
Arm Type
Experimental
Arm Description
3 capsules/day during dinner Per day: 67.2 mg red yeast rice powder (Monascus purpureus; equivalent to 2.9 mg monacoline K) 1000 mg amla dry extract (Phyllanthus emblica) 100 mg walnut leave dry extract (Juglans regia) 50 mg olive dry extract (Olea europaea; equivalent to 10 mg hydroxytyrosol)
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
3 capsules/day during dinner
Intervention Type
Dietary Supplement
Intervention Name(s)
Tensiofytol
Intervention Description
standardized olive extract
Intervention Type
Dietary Supplement
Intervention Name(s)
Cholesfytol NG
Intervention Description
combination preparation
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
contains excipients only
Primary Outcome Measure Information:
Title
Change from baseline Blood Pressure at 8 weeks
Description
average of 3 measurements during 15 minutes
Time Frame
Baseline, 8 weeks
Title
Change from baseline Blood Pressure at 4 weeks
Description
average of 3 measurements during 15 minutes
Time Frame
Baseline, 4 weeks
Title
Change from baseline LDL cholesterol level at 8 weeks
Description
Calculated from Total Cholesterol, HDL Cholesterol and Triglycerides
Time Frame
Baseline, 8 weeks
Title
Change from baseline HDL cholesterol level at 8 weeks
Description
Measurement in Serum
Time Frame
Baseline, 8 weeks
Title
Change from baseline total cholesterol level at 8 weeks
Description
Measurement in Serum
Time Frame
Baseline, 8 weeks
Title
Change from baseline triglycerides level at 8 weeks
Description
Measurement in Serum
Time Frame
Baseline, 8 weeks
Title
Change from baseline glucose level at 8 weeks
Description
Measurement in Fluoride Plasma
Time Frame
Baseline, 8 weeks
Title
Change from baseline insuline level at 8 weeks
Description
Required to correctly interpret glucose levels, Measurement in Serum
Time Frame
Baseline, 8 weeks
Title
Change from baseline Apo A1 level at 8 weeks
Description
Measurement in Serum
Time Frame
Baseline, 8 weeks
Title
Change from baseline Apo B level at 8 weeks
Description
Measurement in Serum
Time Frame
Baseline, 8 weeks
Title
Change from baseline homocysteine level at 8 weeks
Description
Measurement in Homocysteine Serum
Time Frame
Baseline, 8 weeks
Title
Change from baseline lipoprotein A (LP(a)) level at 8 weeks
Description
Measurement in Serum
Time Frame
Baseline, 8 weeks
Title
Change from baseline hs-CRP level at 8 weeks
Description
Measurement in Serum
Time Frame
Baseline, 8 weeks
Title
Change from baseline creatinine level at 8 weeks
Description
Required to correctly interpret HbAc1 levels, Measurement in Serum
Time Frame
Baseline, 8 weeks
Title
Change from baseline HbA1c level at 8 weeks
Description
Measurement in EDTA Whole Blood
Time Frame
Baseline, 8 weeks
Title
Change from baseline hemoglobine level at 8 weeks
Description
Required to correctly interpret HbAc1 levels, Measurement in EDTA Whole Blood
Time Frame
Baseline, 8 weeks
Title
Change from baseline OxLDL level at 8 weeks
Description
Measurement with ELISA
Time Frame
Baseline, 8 weeks
Title
Change from baseline gluathion (GSH) level at 8 weeks
Description
Measurement with in house HPLC method
Time Frame
Baseline, 8 weeks
Title
Change from baseline malondialdehyde (MDA) level at 8 weeks
Description
Measurement with ELISA
Time Frame
Baseline, 8 weeks
Secondary Outcome Measure Information:
Title
Change from baseline creatine kinase (CK) level at 8 weeks
Description
Measurement with ELISA
Time Frame
Baseline, 8 weeks
Title
Change from baseline Body Mass Index (BMI) at 8 weeks
Description
weight and height will be combined to report BMI in kg/m^2
Time Frame
Baseline, 8 weeks
Title
Change from baseline waist circumference at 8 weeks
Description
Measurement with measuring tape
Time Frame
Baseline, 8 weeks
Title
Frequency of side effects (+ their burden) as reported in the final questionnaire
Description
Unvalidated but standardized questionnaire on typical statin-related side effects
Time Frame
8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: LDL cholesterol level ≥ 130 mg/dL Blood pressure ≥ 130/85 mg Hg And at least 2 of the following 4 criteria: Waist circumference > 102 cm for men or > 88 cm for women Triglycerides ≥ 150mg/dL HDL cholesterol < 40mg/dL for men or < 50mg/dL for women Fasting glucose ≥ 110 mg/dL Exclusion Criteria: <18 jaar >70 jaar Smoking Use of nutritional supplements Use of cholesterol lowering medication and/or supplements Triglycerides > 400 mg/dL > 2 alcoholic consumptions/day Chronic illness (e.g. diabetes, atherosclerosis, reumatoid arthritis) Acute infection Current pregnancy or pregnancy wish during the study period Breast feeding When nutritional supplements were used regularly, participation is allowed after a 10-day wash out period. Subjects who used cholesterol lowering medication or nutritional supplements with red yeast rice, can participate after a 6-week wash out.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Stef Lauwers
Phone
003232652706
Email
stef.lauwers@uantwerpen.be
First Name & Middle Initial & Last Name or Official Title & Degree
Nina Hermans, Prof.
Phone
003232652732
Email
nina.hermans@uantwerpen.be
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Johan Bosmans, Prof. MD.
Organizational Affiliation
University Hospital, Antwerp
Official's Role
Principal Investigator
Facility Information:
Facility Name
UAntwerp, NatuRA
City
Wilrijk
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nina Hermans, Prof

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Olive Polyphenols in Cardiovascular Prevention.

We'll reach out to this number within 24 hrs